4dmt presents injection-free subgroup analyses from 4d-150 phase 2 prism randomized dose expansion cohort in wet amd patients with severe disease activity & high treatment burden at the clinical trials at the summit 2024 meeting

Emeryville, calif., june 08, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today presented supplemental aflibercept injection-free subgroup analyses of the previously reported 24-week landmark results from the randomized dose expansion cohort from the phase 2 prism clinical trial evaluating intravitreal 4d-150 in wet age-related macular degeneration (wet amd) patients with severe disease activity and a high treatment burden. the data were presented today at clinical trials at the summit 2024 in park city, utah, by carl danzig, m.d., rand eye institute, deerfield beach, florida.
AMD Ratings Summary
AMD Quant Ranking